ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements
Nectar Lifesciences Limited has announced the appointment of Dr. Gunmala Suri as a Director. Additionally, three other directors have been re-appointed to the Board.
Nectar Lifesciences filed proceedings of its 31st AGM held September 18, 2026. Resolutions covered adoption of FY26 financials and director re-appointments.
Nectar Lifesciences Ltd. has released its Annual Report for FY 2025-26. The 31st Annual General Meeting is scheduled for September 18, 2026, via video conferencing.
Nectar Lifesciences Limited announced a change in its corporate office address, moving to Godrej Eternia in Chandigarh effective September 15, 2026.
Nectar Lifesciences Limited has appointed Dr. Gunmala Suri as an Additional Director, effective August 15, 2026.
Nectar Lifesciences Ltd. has announced that its 31st Annual General Meeting will be held on September 18, 2026. The book closure period is set from September 12, 2026, to September 18, 2026.
Nectar Lifesciences Ltd reported revenue from operations of ₹0.4 Cr and a net loss of ₹15.4 Cr for Q1 FY27.
Nectar Lifesciences Ltd. has scheduled a board meeting on August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Dr. Surulichamy Senthilkumar has resigned as a Non-Executive Non-Independent Director of Nectar Lifesciences Ltd., effective August 06, 2026, due to personal reasons.
Nectar Lifesciences sold its non-core unit, Narbada Industries, including land leasehold rights and machinery, to Shree Balaji Cold Chain & Storage Services for ₹11.22 Crore.
Nectar Lifesciences extended the expected completion date for the slump sale of its Empty Hard Gelatin Capsule business to Capnest Health Care to December 31, 2026.
Nectar LifeSciences Ltd filed its shareholding pattern as per Regulation 31(1)(b), detailing promoter and public holdings as of June 30, 2026. No monetary transaction disclosed.
Nectar Lifesciences shifted its registered office within Dera Bassi, Punjab. This administrative change does not affect the company's operations or statutory registrations.
Nectar Lifesciences appointed Kfin Technologies Limited as its new Registrar and Share Transfer Agent. This follows the withdrawal of a proposal for Alankit Assignments Limited.
Nectar Lifesciences Ltd reported a net loss of ₹67.9 Cr for Q4 FY26.
Nectar Lifesciences reported ₹9.29 Crore total income for FY2025-26. The Board also approved re-appointing two Independent Directors and withdrew the proposal to change its RTA.
Nectar Lifesciences Ltd scheduled a board meeting for May 30, 2026. Directors will consider and approve audited financial results for the 2025-26 fiscal year.
Nectar Lifesciences Limited has extended the completion date for the slump sale of its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited. The parties mutually agreed to extend the expected closing to July 31, 2026. Other transaction terms remain unchanged from the previous disclosure dated December 20, 2025.
Nectar Lifesciences Ltd announced the conclusion of income tax litigation for Assessment Year 2017-18. Following directions from the Punjab and Haryana High Court, the Deputy Commissioner of Income Tax passed an order in favor of the company on March 31, 2026. The matter stands fully concluded with no financial implications or claims.
Nectar Lifesciences Ltd submitted its Annual Secretarial Compliance Report for FY2026. The report highlighted a ₹0.02 Crore fine paid to exchanges for a past delay in filing FY2025 financial results due to the Chairman's health. The auditor confirmed the company has since rectified the default and complied with other SEBI regulations.
Nectar Lifesciences Ltd reported net profit of ₹14.3 Cr (+83.3% YoY) for Q3 FY26.
Nectar Lifesciences Ltd launched its second 100-day 'Saksham Niveshak' campaign from April 1 to July 9, 2026. The initiative assists shareholders in updating KYC details and claiming unpaid dividends to prevent their transfer to the IEPF Authority. Investors are urged to contact KFin Technologies to safeguard their entitlements.
Nectar Lifesciences Limited submitted a compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The certificate from KFin Technologies confirms that security certificates received for dematerialization were processed and mutilated within prescribed timelines. This is a routine administrative filing with no direct financial impact.